Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer

被引:0
作者
Salinas, Erin A. [1 ]
Newtson, Andreea M. [2 ]
Leslie, Kimberly K. [2 ]
Gonzalez-Bosquet, Jesus [1 ]
机构
[1] Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, Div Gynecol Oncol, Iowa City, IA 52242 USA
[2] Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
来源
INTERNATIONAL JOURNAL OF MOLECULAR EPIDEMIOLOGY AND GENETICS | 2016年 / 7卷 / 01期
关键词
Ovarian cancer; chemotherapy; genetic risk; single nucleotide polymorphisms; data analysis;
D O I
暂无
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: A gene signature associated with chemo-response in ovarian cancer was created through integration of biological data in The Cancer Genome Atlas (TCGA) and validated in five independent microarray experiments. Our study aimed to determine if single nucleotide polymorphisms (SNPs) within the 422-gene signature were associated with a genetic predisposition to platinum-based chemotherapy response in serous ovarian cancer. Methods: An association analysis between SNPs within the 422-gene signature and chemo-response in serous ovarian cancer was performed under the log-additive genetic model using the 'SNPassoc' package within the R environment (p < 0.0001). Subsequent validation of statistically significant SNPs was done in the Ovarian Cancer Association Consortium (OCAC) database. Results: 19 SNPs were found to be associated with chemo-response with statistical significance. None of the SNPs found significant in TCGA were validated within OCAC for the outcome of interest, chemo-response. Conclusions: SNPs associated with chemo-response in ovarian cancer within TGCA database were not validated in a larger database of patients and controls from OCAC. New strategies integrating somatic and germline information may help to characterize genetic predictors for treatment response in ovarian cancer.
引用
收藏
页码:41 / 44
页数:4
相关论文
共 7 条
[1]   Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data [J].
Bosquet, Jesus Gonzalez ;
Marchion, Douglas C. ;
Chon, HyeSook ;
Lancaster, Johnathan M. ;
Chanock, Stephen .
CANCER RESEARCH, 2014, 74 (14) :3902-3912
[2]   METASTASIS RESULTS FROM PREEXISTING VARIANT CELLS WITHIN A MALIGNANT-TUMOR [J].
FIDLER, IJ ;
KRIPKE, ML .
SCIENCE, 1977, 197 (4306) :893-895
[3]   Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently? [J].
Friedlander, Michael L. ;
Stockler, Martin Richard ;
Butow, Phyllis ;
King, Madeleine Trudy ;
McAlpine, Jessica ;
Tinker, Anna ;
Ledermann, Jonathan A. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18) :2362-2362
[4]   SNPassoc:: an R package to perform whole genome association studies [J].
Gonzalez, Juan R. ;
Armengol, Lluis ;
Sole, Xavier ;
Guino, Elisabet ;
Mercader, Josep M. ;
Estivill, Xavier ;
Moreno, Victor .
BIOINFORMATICS, 2007, 23 (05) :644-645
[5]   Part I: Chemotherapy for epithelial ovarian cancer - treatment at first diagnosis [J].
Harries, M ;
Gore, M .
LANCET ONCOLOGY, 2002, 3 (09) :529-536
[6]   Cancer statistics, 2005 [J].
Jemal, A ;
Murray, T ;
Ward, E ;
Samuels, A ;
Tiwari, RC ;
Ghafoor, A ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) :10-30
[7]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6